Weight loss as a tag covers the practical clinical question — what actually works, how much, in whom, and for how long — across the full peptide pipeline.
The headline data sources: SURMOUNT-5 (tirzepatide vs semaglutide), ACHIEVE-3 (orforglipron in obesity), TRIUMPH (retatrutide), REDEFINE-1 (CagriSema), the STEP series (semaglutide), and the growing real-world evidence literature on what 12-month outcomes look like outside trial conditions. SURMOUNT-5 set the current high-water mark at 21.6% mean weight loss for tirzepatide; retatrutide Phase 2 went above 24%.
Stories here cover the readouts, the discontinuation and weight-regain data, and the head-to-head comparisons. See #obesity for the broader category and #body-composition for muscle-mass and lean-tissue work.
MetaVia's higher-dose Phase 1 readout for DA-1726 at EASL 2026 produced specific efficacy numbers: the 48 mg cohort in obese but otherwise healthy adults achieved 9.1% mean body-weight reduction and a 9.8 cm waist-circumference reduction at Day 54, with exploratory FibroScan liver improvements and no serious adverse events. DA-1726 is a once-weekly subcutaneous oxyntomodulin analog acting as a 3:1 ratio GLP-1/glucagon dual receptor agonist for obesity and MASH. The 9.1% weight loss in roughly eight weeks is a fast trajectory for an early-phase obesity peptide and supports MetaVia's case heading into the 16-week Phase 1 Part 3 titration study reading out Q4 2026. The waist reduction (a glucagon-receptor-driven visceral-fat signal) and the FibroScan liver improvements position DA-1726 in the dual obesity-and-MASH lane alongside survodutide and pemvidutide. MetaVia's three ADA 2026 late-breaking abstracts (June 7 New Orleans) extend the DA-1726 and vanoglipel data sets.
Published the day after Foundayo's FDA approval, a new indirect comparison found oral semaglutide may produce greater weight loss than orforglipron with fewer GI discontinuations.
With one in ten American adults already on GLP-1 drugs, next-generation medications including Foundayo and retatrutide could reach the ~25% of patients who don't respond to current GLP-1 monotherapies.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
New research finds approximately 25% of weight lost persists after GLP-1 discontinuation. Trajectories were similar across semaglutide, liraglutide, and tirzepatide.